Details of the Drug

General Information of Drug (ID: DMX3IRE)

• Drug Name: HBP-347
• Synonyms: HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Discontinued in Phase 3	[1]

• Cross-matching ID: TTD ID: D03IKZ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Modulator	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Autoimmune diabetes
• ICD Disease Classification: 5A10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Heat shock protein 90 alpha (HSP90A)	DTT	HSP90AA1	3.96E-01	0.18	0.48

References

• [1] Heat shock protein 90 (Hsp90). SciBX 4(18).
• [2] US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors.